trending Market Intelligence /marketintelligence/en/news-insights/trending/oYjj_mypLOb0gWUUHQOhig2 content esgSubNav
In This List

Theralase raises C$1.4M to fund bladder cancer therapy

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Theralase raises C$1.4M to fund bladder cancer therapy

Theralase Technologies Inc. closed a private placement of stock and warrant units to raise about C$1.4 million in gross proceeds, which will be used to develop a bladder cancer treatment.

The Toronto-based healthcare company sold 4,095,157 units priced at 35 Canadian cents apiece in the offering. Theralase Technologies will use the proceeds from the sale to develop its bladder cancer therapy as well as for working capital and general corporate purposes.

Each unit in the offering is made up of 1 common share of Theralase Technologies and a warrant to purchase 1 common share for 50 cents each within 24 months.

Theralase Technologies develops laser technology platforms to destroy cancer cells and treat other diseases.